Jim Januzzi, MD, outlines a multitude of drug treatment options for heart failure revolving around patient ejection fraction (EF) status. Ryan Haumschild, PharmD, MS, MBA: As we start to transition ...

Ejection fraction (EF) measures the amount of blood pumped out of your heart's lower chambers, or ventricles. It's the percentage of blood that leaves your ventricle when your heart contracts. The ...

Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...

Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart ...

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...

Novartis' drug, which combines sacubitril and valsartan, is the first to directly treat patients with heart failure with preserved ejection fraction. FDA on Tuesday granted Entresto, a combination of ...

Population-based studies report that the majority of elderly patients with heart failure have a normal ejection fraction (HF-NEF) and a history of hypertension. Left ventricular diastolic dysfunction, ...